-
Sarcoidosis is a multisystem granulomatous disease most often affecting the lungs, eyes, skin, and liver, with neurological involvement in 5-10%.
-
A Strategy to Reduce Cardiovascular Disease by More Than 80 Percent;
Pearly Penile Papules: Still No Reason for Uneasiness; The Epidemiology
of Major Depressive Disorder; Urinary Tetrahydroaldosterone as a Screen
for Aldosteronism; Finasteride and Prostate Cancer; Impermeable Bed
Covers in Patients with Allergic Rhinitis
-
The FDA has approved vardenafil (LevitraBayer and GlaxoSmithKline) for the treatment of erectile dysfunction in men.
-
Several excellent reviews have considered the advantages and disadvantages of popular diets, including those that feature dietary protein, but none has focused exclusively on a sample of best-seller diets, as enjoyed by the public. This article analyzes the claims of, scientific evidence for, and sustainability of 6 popular bestseller diets, along with their published recipes.
-
A generic form of paroxetine (PaxilGlaxoSmithKline) will soon be on the market. The drug marks the second SSRI antidepressant to go generic after fluoxetine (Prozac) last year.
-
Insulin Plus Metformin vs Triple Oral Therapy in Type 2 Diabetes; ARB
and ACE-I in Diabetic Nephropathy; Low-Glycemic Index Diets and
Diabetes; Ultralow-Dose Estrogen and Bone in Older Women; Effect of
Intensity of Oral Anticoagulation in Atrial Fibrillation; Patient
Knowledge and Awareness of Hypertension
-
Hylek and colleagues report on the effects of varying intensities of oral anticoagulation on the frequency and severity of strokes among patients with atrial fibrillation.
-
The intracoronary stenting with antithrombotic Regimen Cooling Off (ISAR-COOL) study results were initially presented at the 2002 American
Heart Association Scientific Session.
-
The European Trial of Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) study tested the hypothesis that perindopril in patients with stable coronary artery disease, but without heart failure or substantial hypertension, will reduce cardiovascular deaths, myocardial infarction, and cardiac arrest.
-
The 3 CHARM studies (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) and their combined results were presented at the ESC meeting and published in Lancet in September.